BiotechTube
Pharmacosmos

Pharmacosmos

Hillerød, Denmark· Est.
pharmacosmos.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Pharmacosmos is a long-established, private Danish biotech focused on revolutionizing the prevention and treatment of iron deficiency. Leveraging deep expertise in carbohydrate chemistry and iron metabolism, the company has built a commercial portfolio and is advancing a pipeline targeting iron-related disorders. As a family-owned entity, it emphasizes long-term vision, quality, and sustainable growth, with a significant global commercial footprint in over 40 countries.

Iron Deficiency AnaemiaIron OverloadBlood-related Disorders

Technology Platform

Global pioneer in carbohydrate chemistry, with deep expertise in developing iron-carbohydrate complexes for safe and effective intravenous iron delivery and manipulation of iron metabolism.

Opportunities

The massive global prevalence of iron deficiency anaemia (over 1 billion people) provides a sustained and growing market for IV iron therapies.
Expanding into the adjacent iron overload market with a novel chelator (petadeferitrin) addresses a serious unmet need in transfusion-dependent patients and diversifies the company's portfolio.

Risk Factors

High competition in the established IV iron market from large pharma and other specialists.
Pipeline concentration risk, with visible growth dependent on the success of a single development candidate (petadeferitrin).
Business is heavily focused on the iron therapy franchise, creating exposure to class-wide or reimbursement challenges.

Competitive Landscape

In IV iron therapy, Pharmacosmos competes with large pharmaceutical companies (e.g., Vifor Pharma, owned by CSL; American Regent, a Daiichi Sankyo company) and other players like Injectafer (ferric carboxymaltose). In the iron chelator space for overload, it would face competition from established drugs like deferoxamine, deferasirox, and deferiprone.

More companies in Small Molecule Drugs →More companies in Denmark →